RM
+
Box containing capsules of the cancer drug lenvatinib marketed as Lenvima It belongs to a class of drugs known as tyrosine kinase inhibitors which
RM
+
Box containing capsules of the cancer drug lenvatinib marketed as Lenvima It belongs to a class of drugs known as tyrosine kinase inhibitors which
RM
+
Human dual leucine zipper kinase (DLK) complexed with inhibitor molecular model The image shows a ribbon representation of the human dual leucine zi
RM
+
Human dual leucine zipper kinase (DLK) complexed with inhibitor molecular model The image shows a ribbon representation of the human dual leucine zi
RF
+
Rapamycin illustration
RF
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) illustration Atoms are represented as spheres with conventional colour coding hydrogen (
RF
+
Pemigatinib cancer drug molecule illustration Atoms are represented as spheres with conventional colour coding hydrogen (white) carbon (black) ni
RM
+
Trametinib melanoma cancer drug
RM
+
GSK3B enzyme complex with ADP and inhibitor Illustration of the GSK3B enzyme (blue) complexed with molecules of adenosine diphosphate (ADP) and the k
RM
+
GSK3B enzyme complex with ADP and inhibitor illustration
RM
+
GSK3B enzyme complex with kinase inhibitor Illustration of the GSK3B enzyme (blue) complexed with a molecule of the kinase inhibitor drug alsterpaull
RM
+
GSK3B enzyme complex with kinase inhibitor Illustration of the GSK3B enzyme (blue) complexed with a molecule of the kinase inhibitor drug alsterpaull
RM
+
Oncogene tyrosine kinase c-Abl Computer model of the human oncogene protein kinase c-Abl (cyan) with the drug PD 166326 a pyridopyrimidine-type inhi
RM
+
Oncogene tyrosine kinase c-Abl Computer model of the human oncogene protein kinase c-Abl (cyan) with the drug PD 166326 a pyridopyrimidine-type inhi
RM
+
Oncogene tyrosine kinase c-Abl Computer model of the human oncogene protein kinase c-Abl (cyan) with the drug PD 166326 a pyridopyrimidine-type inhi
RM
+
Oncogene tyrosine kinase c-Abl Computer model of the human oncogene protein kinase c-Abl (cyan) with the drug PD 166326 a pyridopyrimidine-type inhi
RM
+
Tyrosine kinase and bosutinib complex Computer illustration showing a molecule of bosutinib (spheres) bound to a tyrosine kinase molecule (grey) Tyr
RM
+
Tyrosine kinase and bosutinib complex Computer illustration showing a molecule of bosutinib (spheres) bound to a tyrosine kinase molecule (ribbons)
RM
+
Tyrosine kinase and bosutinib complex Computer illustration showing a molecule of bosutinib (spheres) bound to a tyrosine kinase molecule (ribbons)
RM
+
Cyclin-dependent kinase inhibitor complex Molecular model of the inhibitor protein P27Kip1 bound to a cyclin-A-cyclin dependent kinase 2 complex Cyc
RM
+
Cyclin-dependent kinase inhibitor complex Molecular model of the inhibitor protein P27Kip1 bound to a cyclin-A-cyclin dependent kinase 2 complex Cyc
RM
+
Proliferating cell nuclear antigen molecule Molecular model of human proliferating cell nuclear antigen (PCNA blue green and red) complexed with i
RM
+
Proliferating cell nuclear antigen molecule Molecular model of human proliferating cell nuclear antigen (PCNA green) complexed with its loader prot
RM
+
Proliferating cell nuclear antigen molecule Molecular model of human proliferating cell nuclear antigen (PCNA) complexed with an end section of the
RM
+
Proliferating cell nuclear antigen molecule Molecular model of human proliferating cell nuclear antigen (PCNA) complexed with an end section of the
RM
+
Tyrosine kinase ABL1 enzyme molecular model showing secondary structure This protein is an enzyme that plays a role in the functioning of the ABL1 h
RM
+
Protein kinase research
RM
+
Protein kinase research Synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and their use in d
RM
+
Protein kinase research
RM
+
Protein kinase research
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher holding a rack of test tubes being used in the synthesis of protein kinases as part of research to determine the s
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher synthesising protein kinases as part of research to determine the selectivity of protein kinase inhibitors and the
RM
+
Protein kinase research Researcher analysing protein kinases using a radioactive (33P-ATP) filter-binding assay This is part of research to determin
RM
+
Protein kinase research Researcher analysing protein kinases using a radioactive (33P-ATP) filter-binding assay This is part of research to determin
RM
+
Protein kinase research Researcher analysing protein kinases using a radioactive (33P-ATP) filter-binding assay This is part of research to determin
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
Kinase profiling Researcher analysing protein kinase inhibitors to determine their selectivity as part of research into drug targeting This techniqu
RM
+
AKT1 human enzyme molecule Computer model showing the secondary structure of a molecule of RAC-alpha serinethreonine-protein kinase (AKT1 white) i
RM
+
AKT1 human enzyme molecule Computer model showing the quaternary structure of a molecule of RAC-alpha serinethreonine-protein kinase (AKT1 white)
RM
+
AKT1 human enzyme molecule Computer model showing the quaternary structure of a molecule of RAC-alpha serinethreonine-protein kinase (AKT1 white)
RM
+
AKT1 human enzyme molecule Computer model showing the secondary structure of a molecule of RAC-alpha serinethreonine-protein kinase (AKT1 white) i
RM
+
Tyrosine kinase and inhibitor molecule Molecular model of a mammalian tyrosine kinase molecule (green ribbons) with an inhibitor (blue spheres) bound
RM
+
DAPK3 and Pyridone 6 proteins Molecular model of death-associated protein kinase 3 (DAPK3) also called dual leucine zipper kinase (ZIPK) complexing
RM
+
Kinase molecule computer model Kinases are enzymes that catalyse the transfer of phosphate groups from a high-energy phosphate-containing molecule (
RF
+
Crizotinib anti-cancer drug molecule Inhibitor of ALK and ROS1 proteins Stylized skeletal formula (chemical structure) Atoms are shown as color-cod
RF
+
Crizotinib anti-cancer drug molecule
RF
+
Trametinib melanoma cancer drug molecular model Atoms are represented as spheres and are colour-coded hydrogen (white) carbon (grey) oxygen (red)
RF
+
Trametinib melanoma cancer drug molecular model Atoms are represented as spheres and are colour-coded hydrogen (white) carbon (grey) oxygen (red)
RF
+
Kinase inhibitor complex Molecular model of a leucettine kinase inhibitor bound to a serine threonine kinase protein
RF
+
cAMP-dependent protein kinase Molecular model of cAMP-dependent protein kinase complexed with a peptide inhibitor and ATP (adenosine triphosphate) T
RF
+
Kinase inhibitor complex Molecular model of a leucettine kinase inhibitor bound to a serine threonine kinase protein
RF
+
cAMP-dependent protein kinase Molecular model of cAMP-dependent protein kinase complexed with a peptide inhibitor and ATP (adenosine triphosphate) T
RF
+
Trametinib melanoma cancer drug molecular model Atoms are represented as spheres and are colour-coded hydrogen (white) carbon (grey) oxygen (red)
RF
+
Trametinib melanoma cancer drug molecular model Atoms are represented as spheres and are colour-coded hydrogen (white) carbon (grey) oxygen (red)
RF
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles hy
RF
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles hy
RF
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) Skeletal formula
RF
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) Skeletal formula
RF
+
Cyclic guanosine monophosphate (cGMP) molecule Important second messenger produced by guanylate cyclase broken down by phosphodiesterase (PDE) Sty
RF
+
Cyclic guanosine monophosphate (cGMP) molecule Important second messenger produced by guanylate cyclase broken down by phosphodiesterase (PDE) Whi
RF
+
Cyclic guanosine monophosphate molecule illustration
RF
+
Cyclic guanosine monophosphate (cGMP) molecule Important second messenger produced by guanylate cyclase broken down by phosphodiesterase (PDE) Blu
RF
+
Volasertib cancer drug molecule (PLK1 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles with thick bl
RF
+
Volasertib cancer drug molecule (PLK1 inhibitor) White skeletal formula on dark teal gradient background with hexagonal pattern
RF
+
Volasertib cancer drug molecule (PLK1 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles connected by
RF
+
Volasertib cancer drug molecule (PLK1 inhibitor) Blue skeletal formula on white background
RF
+
Tideglusib drug molecule (GSK-3 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles with thick black ou
RF
+
Tideglusib drug molecule (GSK-3 inhibitor) White skeletal formula on dark teal gradient background with hexagonal pattern
RF
+
Tideglusib drug molecule (GSK-3 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles connected by thin b
RF
+
Tideglusib drug molecule (GSK-3 inhibitor) Blue skeletal formula on white background
RF
+
Netarsudil drug molecule Used in treatment of ocular hypertension and glaucoma Stylized skeletal formula (chemical structure) atoms are shown as co
RF
+
Netarsudil drug molecule Used in treatment of ocular hypertension and glaucoma White skeletal formula on dark teal gradient background with hexagona
RF
+
Netarsudil drug molecule Used in treatment of ocular hypertension and glaucoma Stylized skeletal formula (chemical structure) atoms are shown as co
RF
+
Netarsudil drug molecule Used in treatment of ocular hypertension and glaucoma Blue skeletal formula on white background
RF
+
Midostaurin cancer drug molecule (protein kinase inhibitor) Stylized skeletal formula (chemical structure) atoms are shown as color-coded circles wi
RF
+
Midostaurin cancer drug molecule (protein kinase inhibitor) White skeletal formula on dark teal gradient background with hexagonal pattern
RF
+
Midostaurin cancer drug molecule (protein kinase inhibitor) Stylized skeletal formula (chemical structure) atoms are shown as color-coded circles co
RF
+
Midostaurin cancer drug molecule (protein kinase inhibitor) Blue skeletal formula on white background
RF
+
Crizotinib anti-cancer drug molecule Inhibitor of ALK and ROS1 proteins Stylized skeletal formula (chemical structure) Atoms are shown as color-cod
RF
+
Crizotinib anti-cancer drug molecule Inhibitor of ALK and ROS1 proteins White skeletal formula on dark teal gradient background with hexagonal patte
RF
+
Crizotinib anti-cancer drug molecule Inhibitor of ALK and ROS1 proteins Stylized skeletal formula (chemical structure) Atoms are shown as color-cod
RF
+
Crizotinib anti-cancer drug molecule Inhibitor of ALK and ROS1 proteins Blue skeletal formula on white background
RM
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles wit
RM
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) White skeletal formula on dark teal gradient background with hexagonal pattern MOLEKUUL
RM
+
Selumetinib cancer drug molecule (MEK1 and MEK2 inhibitor) Stylized skeletal formula (chemical structure) Atoms are shown as color-coded circles con
124
0
https://www.afloimages.com/search/protein%20kinase%20inhibitor.html